Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesChk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle GrowthmTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibitionIdentification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cellsRationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticRuxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROSCell death by autophagy: emerging molecular mechanisms and implications for cancer therapy.Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.Targeting the ATR-CHK1 Axis in Cancer TherapyThe emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.ATR/CHK1 inhibitors and cancer therapy.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
P2860
Q26745686-D5C2EC83-3350-4BB0-A8CB-09D221724972Q26864870-2CB5B464-189C-4A21-885B-19EB13170827Q34062570-D5F30D95-8BA5-4A57-8896-B2395EAB3B2DQ34536058-6C31842C-478F-4F1F-98A4-0778A7941322Q35809470-7D55C5ED-A9F1-4D6D-BEE5-E2D0B88DF48EQ36294441-583A6AE4-A199-4FA4-866B-C060CCBD0372Q36901517-87B43078-C89A-484D-BBC9-0D22024A40C4Q36995729-33AA1720-989C-4184-914A-46616E4931DDQ37109457-9AF4B9A2-B197-4C91-8A3A-FB51D7D05B76Q38331755-956673B7-6598-4E11-A80F-39E83D00BB35Q38805276-9C30B588-0D4F-4510-ABF7-53AE0A3385C3Q38817102-30858EEA-E65E-46BF-9D08-5A74ED8AC332Q39190147-2BB4C234-9742-4213-A50C-70F2D9DE234DQ47622968-8C929BAE-D712-4B60-A0A7-3EFEF56E7DF4Q50187396-57CD9399-8267-4147-949F-A7B247F11E56
P2860
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@ast
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@en
type
label
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@ast
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@en
prefLabel
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@ast
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@en
P2093
P2860
P356
P1476
Poly(ADP-ribose) polymerase 1 ...... inhibitors in mammary tumors.
@en
P2093
Andrew Poklepovic
Hossein A Hamed
Steven Grant
P2860
P304
P356
10.1124/MOL.112.078907
P50
P577
2012-05-17T00:00:00Z